Skip to main content
SpringerLink
Log in

Serum prolidase level in ankylosing spondylitis: low serum levels as a new potential gold standard biomarker for disease activity

  • Biomarkers
  • Published:
Rheumatology International Aims and scope Submit manuscript

Abstract

Ankylosing spondylitis (AS) is a chronic inflammatory disorder that mainly affects the sacroiliac joints and axial skeleton. The aim of this study was to assess serum prolidase level (SPL) and its association with disease activity in patients with AS. This prospective study included 75 AS patients. Thirty age- and gender-matched healthy controls were enrolled. AS patients were considered as active if BASDAI score was ≥4 or inactive if BASDAI score was <4. There were 34 AS patients in the active group and 41 AS patients in the inactive group. Anti-TNF-monoclonal antibody treatment was started in patients in the active group. These active patients were reassessed 6 months later. BASDAI, ASDAS, visual analogue scale, short-form-general health survey questionnaire, C-reactive protein, erythrocyte sedimentation rate and SPL were measured in all AS patients before and after treatment. The SPL was significantly lower in inactive AS patients than in control group, and also, SPL was significantly lower in active AS patients than in inactive patients. All activity parameters were successful in separating active and inactive AS patients. However, the only parameter that could distinguish active patients from inactive patients was prolidase. The optimum cutoff point of SPL to identify patients with active AS was 23.13 ng/mL with sensitivity, specificity, positive predictive value and negative predictive value of 100 %. Serum prolidase level was successful in measuring disease activity and had as high sensitivity and specificity as BASDAI and was superior to other activity parameters.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Schett G (2009) Bone formation versus bone resorption in ankylosing spondylitis. Adv Exp Med Biol 649:114–121

    Article  CAS  PubMed  Google Scholar 

  2. Arends S, Spoorenberg A, Bruyn GA, Houtman PM, Leijsma MK, Kallenberg CG, Brouwer E, van de Veer E (2011) The relation between bone mineral density, bone turnover markers, and vitamin D status in ankylosing spondylitis patients with active disease: a cross-sectional analysis. Osteoporos Int 22:1431–1439

    Article  CAS  PubMed  Google Scholar 

  3. Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A (1994) A new approach to defining disease status in ankylosing spondylitis: the bath ankylosing spondylitis disease activity index. J Rheumatol 21:2286–2291

    CAS  PubMed  Google Scholar 

  4. Van der Heijde D, Lie E, Kvien TK, Sieper J, Van den Bosch F, Listing J, Braun J, Landewé R (2009) ASDAS, a highly discriminatory ASAS-endorsed disease activity score in patients with ankylosing spondylitis. Ann Rheum Dis 68:1811–1818

    Article  PubMed  Google Scholar 

  5. Turina MC, Sieper J, Yeremenko N, Conrad K, Haibel H, Rudwaleit M, Baeten D, Poddubnyy D (2014) Calprotectin serum level is an independent marker for radiographic spinal progression in axial spondyloarthritis. Ann Rheum Dis 73:1746–1748

    Article  PubMed  Google Scholar 

  6. Bettencourt BF, Rocha FL, Alves H, Amorim R, Caetano-Lopes J, Vieira-Sousa E, Pimentel-Santos F, Lima M, Porto G, Branco JC, Fonseca JE, Bruges-Armas J (2013) Protective effect of an ERAP1 haplotype in ankylosing spondylitis: in-vestigating non-MHC genes in HLA-B27-posi-tive individuals. Rheumatology (Oxford) 52:2168–2176

    Article  CAS  Google Scholar 

  7. Cechowska-Pasko M, Pałka J, Wojtukiewicz MZ (2006) Enhanced prolidase activity and decreased collagen content inbreast cancer tissue. Int J Exp Pathol 87:289–296

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Horoz M, Aslan M, Bolukbas FF, Bolukbas C, Nazligul Y, CelikH Aksoy N (2010) Serum prolidase enzyme activity and itsrelation to histopathological findings in patients with non-alcoholicsteatohepatitis. J Clin Lab Anal 24:207–211

    Article  CAS  PubMed  Google Scholar 

  9. Wolańska M, Sobolewski K, Drozdzewicz M (2001) Integrins and prolidase activity in uterine leiomyoma during tumor growth. Ginekol Pol 72:121–126

    PubMed  Google Scholar 

  10. Hui KS, Lajttia A (1978) Prolidase activity in brain: comparison with other organs. J Neurochem 30:320–327

    Article  Google Scholar 

  11. Altindag O, Erel O, Aksoy N, Selek S, Celik H, Karaoglanoglu M (2007) Increased oxidative stress and its relation with collagen metabolism in knee osteoarthritis. Rheumatol Int 27:339–344

    Article  CAS  PubMed  Google Scholar 

  12. Marotte H, Gineyts E, Miossec P (2010) Prolidase deficiency: a rare aetiology of arthritis. Joint Bone Spine 77:88–89

    Article  PubMed  Google Scholar 

  13. Uçar D, Em S, Bozkurt M, Oktayoglu P, Yüksel HK, Caglayan M, Gezer O, Nas K (2013) Serum prolidase activity in ankylosing spondylitis and rheumatoid arthritis. Clin Med Insights Arthritis Musculoskelet Disord 6:29–33

    Article  PubMed  PubMed Central  Google Scholar 

  14. Van der Linden SM, Valkenburg HA, Cats A (1984) Evaluation of diagnostic criteria for ankylosing spondylitis: a proposal for modificationof the New York criteria. Arthritis Rheum 27:361–368

    Article  PubMed  Google Scholar 

  15. Hemingway H, Stafford M, Stansfeld S, Shipley M, Marmot M (1997) Is the SF-36 a valid measure of change in population health? Results from the Whitehall II Study. BMJ 315:1273–1279

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Machado P, Landewé R, Lie E, Kvien TK, Braun J, Baker D, van der Heijde D (2011) Ankylosing Spondylitis Disease Activity Score (ASDAS): defining cut-off values for diseaseactivity states and improvement scores. Ann Rheum Dis 70:47–53

    Article  PubMed  Google Scholar 

  17. Przepiera-Bwdzak H, Fischer K, Brzosko M (2015) Serum IL-6 and IL-23 levels and their correlation withangiogenic cytokines and disease activity in ankylosing spondylitis, psoriatic arthritis, and SAPHO syndrome. Mediat Inflamm. doi:10.1155/2015/785705

    Google Scholar 

  18. Rudwaleit M, Haibel H, Baraliakos X, Listing J, Marker-Hermann E, Zeidler H, Braun J, Sieper J (2009) The early disease stage in axial spondylarthritis: results from the German Spondyloarthritis Inception Cohort. Arthritis Rheum 60:717–727

    Article  CAS  PubMed  Google Scholar 

  19. Oktayoglu P, Bozkurt M, Mete N, Caglayan M, Em S, Nas K (2014) Elevated serum levels of calprotectin (myeloid-related protein 8/14) in patients with ankylosing spondylitis and its association with disease activity and quality of life. J Investig Med 62:880–884

    Article  CAS  PubMed  Google Scholar 

  20. Sveaas SH, Berg IJ, Provan SA, Semb AG, Olsen IC, Ueland T, Aukrust P, Vollestad N, Hagen KB, Kvien TK, Dagfinrud H (2015) Circulating levels of inflammatory cytokines and cytokine receptors in patients with ankylosing spondylitis: a cross-sectional comparative study. Scand J Rheumatol 44:118–124

    Article  CAS  PubMed  Google Scholar 

  21. Andersen T, Rasmussen TK, Hvid M, Holm CK, Madsen KJ, Jurik AG et al (2012) Increased plasma levels of IL-21 and IL-23 in spondyloarthritis are not associated with clinical and MRI findings. Rheumatol Int 32:387–393

    Article  CAS  PubMed  Google Scholar 

  22. Mattey DL, Packham JC, Nixon NB, Coates L, Creamer P, Hailwood S, Taylor GJ, Bhalla AK (2012) Association of cytokine and matrix metalloproteinase profiles with disease activity and function in ankylosing spondylitis. Arthritis Res Ther 14:127

    Article  Google Scholar 

  23. Korkosz M, Gąsowski J, Leszczyński P, Pawlak-Buś K, Jeka S, Kucharska E, Grodzicki T (2013) High disease activity in ankylosing spondylitis is associated with increased serum sclerostin level and decreased wingless protein-3a signaling but is not linked with greater structural damage. BMC Musculoskelet Disord 14:99

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Visvanathan S, van der Heijde D, Deodhar A, Wagner C, Baker DG, Han J et al (2009) Effects of infliximab on markers of inflammation and bone turnover and associations with bone mineral density in patients with ankylosing spondylitis. Ann Rheum Dis 68:175–182

    Article  CAS  PubMed  Google Scholar 

  25. Londono J, Romero-Sanchez MC, Torres VG, Bautista WA, Fernandez DJ, Qurioga Jde A et al (2012) The association between serum levels of potential biomarkers withthe presence of factors related to the clinical activity and poorprognosis in spondyloarthritis. Revista Brasileira de Reumatologia 52:536–544

    Article  PubMed  Google Scholar 

  26. Wendling D, Cedoz JP, Racadot E (2009) Serum and synovialfluid levels of p40 IL12/23 in spondyloarthropathy patients. Clin Rheumatol 28:187–190

    Article  PubMed  Google Scholar 

  27. Gao R, Sun W, Chen Y, Su Y, Wang C, Dong L (2015) Elevated serum levels of soluble CD30 in ankylosing spondylitis patients and its association with disease severity-related parameters. Biomed Res Int. doi:10.1155/2015:617282

    Google Scholar 

  28. Altay MA, Ertürk C, Bilge A, Yaptı M, Levent A, Aksoy N (2015) Evaluation of prolidase activity and oxidative status in patients with knee osteoarthritis: relationships with radiographic severity and clinical parameters. Rheumatol Int 35:1725–1731

    Article  CAS  PubMed  Google Scholar 

  29. Braun J, Brandt J, Listing J, Zink A, Alten R, Golder W et al (2002) Treatment of active ankylosing spondylitis with infliximab: arandomised controlled multicentre trial. Lancet 359:1187–1193

    Article  CAS  PubMed  Google Scholar 

  30. Maksymowych WP, Inman RD, Salonen D, Dhillon SS, KrishnananthanR Stone M et al (2005) Spondyloarthritis research consortium of Canada magnetic resonance imaging index for assessment of spinal inflammation in ankylosing spondylitis. Arthritis Rheum 53:502–509

    Article  PubMed  Google Scholar 

  31. Star VL, Hochberg MC (1994) Osteoporosis in patients with rheumatic diseases. Rheum Dis Clin North Am 20:561–576

    CAS  PubMed  Google Scholar 

  32. Dischereit G, Tarner IH, Müller-Ladner U, Lange U (2013) Infliximab improves bone metabolism and bone mineral density in rheumatoid arthritis and anky-losing spondylitis: a prospective 2-year study. Clin Rheumatol 32:377–381

    Article  PubMed  Google Scholar 

  33. Bozkurt M, Caglayan M, Oktayoglu P, Em S, Batmaz I, Sariyildiz MA, Nas K, Ucar D, Yüksel H, Sarac AJ (2014) Serum prolidase enzyme activity and oxidative status in patients with fibromyalgia. Redox Rep 19:148–153

    Article  CAS  PubMed  Google Scholar 

  34. Bozkurt M, Yüksel H, Em S, Oktayoglu P, Yildiz M, Akdeniz D, Nas K (2014) Serum prolidase enzyme activity and oxidative status in patients with Behçet’s disease. Redox Rep 19:59–64

    Article  CAS  PubMed  Google Scholar 

  35. Butbul Aviel Y, Mandel H, Avitan Hersh E, Bergman R, Adiv OE, Brik R (2012) Prolidase deficiency asso-ciated with systemic lupus erythematosus (SLE): single site experience and literature review. Pediatr Rheumatol Online J 10:18. doi:10.1186/1546-0096-10-18

    Article  PubMed  PubMed Central  Google Scholar 

  36. Savas E, Aksoy N, Pehlivan Y, Sayiner ZA, Oztürk ZA, Tabur S, Orkmez M, Onat AM (2014) Evaluation of oxidant and antioxidant status and relation with prolidase in systemic sclerosis. Wien Klin Wochenschr 126:341–346

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

We thank the Physical Treatment and Rehabilitation Clinic of Erciyes University Medical School for kind help. The study was not supported.

Author information

Authors and Affiliations

  1. Department of Physical Treatment and Rehabilitation, Erciyes University Medical School, 38039, Kayseri, Turkey

    Sevgi Baspinar & Mehmet Kırnap

  2. Department of Internal Medicine, Kayseri Training and Research Hospital, 38010, Kayseri, Turkey

    Osman Baspınar

  3. Department of Internal Medicine and Clinical Nutrition, Kayseri Training and Research Hospital, Atatürk Avenue Hastane street No:78, Kocasinan, 38010, Kayseri, Turkey

    Oguzhan Sıtkı Dizdar

  4. Department of Biochemistry, Kayseri Training and Research Hospital, 38010, Kayseri, Turkey

    Derya Kocer

Authors
  1. Sevgi Baspinar
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mehmet Kırnap
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Osman Baspınar
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Oguzhan Sıtkı Dizdar
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Derya Kocer
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Oguzhan Sıtkı Dizdar.

Ethics declarations

Conflict of interest

Sevgi Baspinar, Oguzhan Sıtkı Dizdar, Osman Baspınar, Derya Kocer and Mehmet Kırnap declare that they have no conflict of interest.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.

Informed consent

Informed consent was obtained from all individual participants included in the study.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Baspinar, S., Kırnap, M., Baspınar, O. et al. Serum prolidase level in ankylosing spondylitis: low serum levels as a new potential gold standard biomarker for disease activity. Rheumatol Int 36, 1609–1616 (2016). https://doi.org/10.1007/s00296-016-3536-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00296-016-3536-x

Keywords

Search

Navigation